Lakefront Biotherapeutics Sells Preclinical Cell Therapy Programs to Armed Cell Therapeutics
Lakefront Biotherapeutics NV (EURONEXT:LKFT) has completed the sale of its early-stage preclinical cell therapy pipeline to Armed Cell Therapeutics BV. Under the terms of the agreement, Lakefront received an upfront payment of 8 million euros and remains eligible for up to $230 million in potential milestone payments, alongside low-single-digit royalties on future sales.
The transaction substantially completes Lakefront's previously announced plan to wind down its legacy cell therapy business. The transferred preclinical assets include multi-targeting and armed CAR-T constructs designed to address treatment resistance in blood cancers and solid tumors. Armed Cell Therapeutics, a Belgium-based biotechnology company formed by experienced industry executives, will independently advance the assets.
Following the sale, Lakefront is focusing its resources on its clinical-stage portfolio in immunology and inflammation. Investors will monitor progress on gamgertamig, its potential first-in-class T-cell engager candidate for autoimmune diseases, supported by its cash position and pipeline.
Key points
- Lakefront Biotherapeutics sold its preclinical CAR-T cell therapy programs to Armed Cell Therapeutics.
- The deal includes an 8 million euro upfront payment and up to $230 million in potential milestone payments.
- Lakefront is also eligible to receive low-single-digit royalties on potential future program sales.
- The transaction substantially completes Lakefront's wind-down of its legacy cell therapy activities.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What did Lakefront Biotherapeutics sell to Armed Cell Therapeutics?
Lakefront Biotherapeutics sold its preclinical cell therapy pipeline, including multi-targeting and armed CAR-T constructs for cancer research.
What are the financial terms of the Lakefront Biotherapeutics deal?
Lakefront received an upfront payment of 8 million euros, with potential for up to $230 million in future milestone payments and low-single-digit royalties.
Why did Lakefront Biotherapeutics divest its cell therapy assets?
The sale substantially completes Lakefront's strategic wind-down of its legacy cell therapy business so it can focus on immunology and inflammation programs.